Legislation Reintroduced to Address Illicit Xylazine While Maintaining Veterinary Access

The Combating Illicit Xylazine Act aims to classify xylazine as a Schedule III controlled substance, granting the Drug Enforcement Administration (DEA) greater authority to regulate its distribution and curb its illicit use. The bill is designed to maintain veterinarians’ legal access while providing oversight of the legitimate supply chain. Both the DEA and the Food and Drug Administration (FDA) have expressed support for the legislation.